Details

Autor(en) / Beteiligte

• Apolo, Andrea B
• Nadal, Rosa
• Girardi, Daniel M
• Niglio, Scot A
• Ley, Lisa
• Cordes, Lisa M
• Steinberg, Seth M
• Sierra Ortiz, Olena
• Cadena, Jacqueline
• Diaz, Carlos
• Mallek, Marissa
• Davarpanah, Nicole N
• Costello, Rene
• Trepel, Jane B
• Lee, Min-Jung
• Merino, Maria J
• Bagheri, Mohammad Hadi
• Monk, Paul
• Figg, William D
• Gulley, James L
• Agarwal, Piyush K
• Valera, Vladimir
• Chalfin, Heather J
• Jones, Jennifer
• Streicher, Howard
• Wright, John J
• Ning, Yangmin M
• Parnes, Howard L
• Dahut, William L
• Bottaro, Donald P
• Lara, Jr, Primo N
• Saraiya, Biren
• Pal, Sumanta K
• Stein, Mark N
• Mortazavi, Amir

Titel

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Ist Teil von

• Journal of clinical oncology, 2020-11, Vol.38 (31), p.3672-3684

Ort / Verlag

United States: American Society of Clinical Oncology

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• We assessed the safety and efficacy of cabozantinib and nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignances. Patients received escalating doses of CaboNivo or CaboNivoIpi. The primary objective was to establish a recommended phase II dose (RP2D). Secondary objectives included objective response rate (ORR), progression-free survival (PFS), duration of response (DoR), and overall survival (OS). Fifty-four patients were enrolled at eight dose levels with a median follow-up time of 44.6 months; data cutoff was January 20, 2020. Grade 3 or 4 treatment-related adverse events (AEs) occurred in 75% and 87% of patients treated with CaboNivo and CaboNivoIpi, respectively, and included fatigue (17% and 10%, respectively), diarrhea (4% and 7%, respectively), and hypertension (21% and 10%, respectively); grade 3 or 4 immune-related AEs included hepatitis (0% and 13%, respectively) and colitis (0% and 7%, respectively). The RP2D was cabozantinib 40 mg/d plus nivolumab 3 mg/kg for CaboNivo and cabozantinib 40 mg/d, nivolumab 3 mg/kg, and ipilimumab 1 mg/kg for CaboNivoIpi. ORR was 30.6% (95% CI, 20.0% to 47.5%) for all patients and 38.5% (95% CI, 13.9% to 68.4%) for patients with mUC. Median DoR was 21.0 months (95% CI, 5.4 to 24.1 months) for all patients and not reached for patients with mUC. Median PFS was 5.1 months (95% CI, 3.5 to 6.9 months) for all patients and 12.8 months (95% CI, 1.8 to 24.1 months) for patients with mUC. Median OS was 12.6 months (95% CI, 6.9 to 18.8 months) for all patients and 25.4 months (95% CI, 5.7 to 41.6 months) for patients with mUC. CaboNivo and CaboNivoIpi demonstrated manageable toxicities with durable responses and encouraging survival in patients with mUC and other GU tumors. Multiple phase II and III trials are ongoing for these combinations.